Quốc gia: Ai-len
Ngôn ngữ: Tiếng Anh
Nguồn: HMA (Heads of Medicines Agencies)
marbofloxacin 80 mg
Emdoka bvba
QJ01MA
Tablet
Fluoroquinolones
Cats Non Food, Dogs Non Food
2013-06-26
Issued: September 2013 AN: 00538/2012 Page 1 of 6 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Marbocare flavour 5mg tablets for dogs and cats (UK and IE) Marbocare F 5mg tablets for dogs and cats (FR) Odimar 5mg tablets for dogs and cats (BE, LU, NL) Marbofloxacin WDT 5mg flavoured tablets for cats and dogs (AT, DE) Marbofloxacino Emdoka 5mg tablets for cats and dogs (ES) Marbofloxacina Emdoka 5mg tablets for cats and dogs (PT) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION EACH TABLET CONTAINS: ACTIVE SUBSTANCE: Marbofloxacin 5.0 mg EXCIPIENTS: For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet Beige brown spotted round tablets with a score line on one side. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs and Cats 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Marbofloxacin is indicated in the treatment of the following infections caused by susceptible strains of organisms (see section 5.1); Dogs Skin and soft tissue infections (skinfold pyoderma, impetigo, folliculitis, furunculosis, cellulitis) Urinary tract infections (UTI) associated or not with prostatitis or epididymitis Respiratory tract infections Issued: September 2013 AN: 00538/2012 Page 2 of 6 Cats Skin and soft tissue infections (wounds, abscesses, phlegmons) Upper respiratory tract infections 4.3 CONTRAINDICATIONS Do not use in dogs aged less than 12 months, or less than 18 months for exceptionally large breeds of dogs, such as Great Danes, Briard, Bernese, Bouvier and Mastiffs, with a longe Đọc toàn bộ tài liệu